Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G ROSENBLUM

Showing results (151-160 of 243) with videos related to

Pageof 25
Sort By:
Journal of Immunological Methods|May 20, 2020
A novel in vivo model using immunotoxin in the absence of p-glycoprotein to achieve ultra selective depletion of target cells: Applications in trogocytosis and beyondKathryn Brown, Lucy Meader, Anna Nowocin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1988
Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancerY Z Patt, L M Lamki, T P Haynie, et al.
Cancer Research|April 15, 1991
Phase I pharmacokinetic study of intraperitoneal etoposideP J O'Dwyer, F P LaCreta, J P Daugherty, et al.
Cancer Research|October 1, 1985
Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinantsZ Krizan, J L Murray, E M Hersh, et al.
Cancer Letters|March 6, 2012
Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxinMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
MMWR. Morbidity and Mortality Weekly Report|August 11, 2022
COVID-19 Self-Test Data: Challenges and Opportunities - United States, October 31, 2021-June 11, 2022Matthew D Ritchey, Hannah G Rosenblum, Kim Del Guercio, et al.
Cancer Research|November 17, 2006
Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGelKhalid A Mohamedali, Ann T Poblenz, Charles R Sikes, et al.
Chaos (Woodbury, N.Y.)|June 5, 2003
From 1/f noise to multifractal cascades in heartbeat dynamicsPlamen Ch. Ivanov, Luis A. Nunes Amaral, Ary L. Goldberger, et al.
Oncogene|February 17, 2015
Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacyM B Berstad, L H Cheung, K Berg, et al.
Biochemical Pharmacology|July 27, 2010
The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphomaMi-Ae Lyu, Bokyung Sung, Lawrence H Cheung, et al.
Pageof 25

Showing results (151-160 of 243) with videos related to

Sort By:
Pageof 25
Journal of Immunological Methods|May 20, 2020
A novel in vivo model using immunotoxin in the absence of p-glycoprotein to achieve ultra selective depletion of target cells: Applications in trogocytosis and beyondKathryn Brown, Lucy Meader, Anna Nowocin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1988
Improved tumor localization with increasing dose of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancerY Z Patt, L M Lamki, T P Haynie, et al.
Cancer Research|April 15, 1991
Phase I pharmacokinetic study of intraperitoneal etoposideP J O'Dwyer, F P LaCreta, J P Daugherty, et al.
Cancer Research|October 1, 1985
Increased labeling of human melanoma cells in vitro using combinations of monoclonal antibodies recognizing separate cell surface antigenic determinantsZ Krizan, J L Murray, E M Hersh, et al.
Cancer Letters|March 6, 2012
Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxinMi-Ae Lyu, Lawrence H Cheung, Walter N Hittelman, et al.
MMWR. Morbidity and Mortality Weekly Report|August 11, 2022
COVID-19 Self-Test Data: Challenges and Opportunities - United States, October 31, 2021-June 11, 2022Matthew D Ritchey, Hannah G Rosenblum, Kim Del Guercio, et al.
Cancer Research|November 17, 2006
Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGelKhalid A Mohamedali, Ann T Poblenz, Charles R Sikes, et al.
Chaos (Woodbury, N.Y.)|June 5, 2003
From 1/f noise to multifractal cascades in heartbeat dynamicsPlamen Ch. Ivanov, Luis A. Nunes Amaral, Ary L. Goldberger, et al.
Oncogene|February 17, 2015
Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacyM B Berstad, L H Cheung, K Berg, et al.
Biochemical Pharmacology|July 27, 2010
The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphomaMi-Ae Lyu, Bokyung Sung, Lawrence H Cheung, et al.
Pageof 25